SCHEMBL5374521

SCHEMBL5374521

CC/C=C\C/C=C\CC1OC1CCCCCCCC(=O)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.60
ALDH1A1 P00352 9/20 0.56
F7 P08709 6/20 0.56
F3 P13726 6/20 0.56
CYP19A1 P11511 5/20 0.56
PPARG P37231 5/20 0.56
OXER1 Q8TDS5 4/20 0.56
PPARD Q03181 4/20 0.56
PPARA Q07869 4/20 0.56
PTGS1 P23219 4/20 0.56
FFAR1 O14842 3/20 0.56
KMT2A Q03164 2/20 0.56
KDM4E B2RXH2 2/20 0.56
LMNA P02545 2/20 0.56
CYP3A4 P08684 2/20 0.56
HPGD P15428 2/20 0.56
ALOX15 P16050 2/20 0.56
FFAR4 Q5NUL3 2/20 0.56
HSD17B10 Q99714 2/20 0.56
TDP1 Q9NUW8 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3742738 1.00 MAPT (0.60) MAPTALDH1A1F7F3CYP19A1
SCHEMBL3742740 1.00 MAPT (0.60) MAPTALDH1A1F7F3CYP19A1
SCHEMBL6244558 0.96 MAPT (0.54) MAPTALDH1A1F7F3CYP19A1
SCHEMBL653863 0.94 MAPT (0.63) MAPTALDH1A1F7F3CYP19A1
SCHEMBL3742728 0.91 MAPT (0.50) MAPTALDH1A1F7F3CYP19A1
SCHEMBL17547609 0.91 MAPT (0.50) MAPTALDH1A1F7F3CYP19A1
SCHEMBL3746335 0.90 MAPT (0.54) MAPTALDH1A1F7F3CYP19A1
SCHEMBL17547604 0.90 MAPT (0.54) MAPTALDH1A1F7F3CYP19A1
SCHEMBL13442941 0.89 CNR1 (0.50) MAPTALDH1A1F7F3CYP19A1
SCHEMBL3735864 0.89 MAPT (0.72) MAPTALDH1A1F7F3CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250216407-A1 LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS INIPHARM, INC. 2025-07-03 US claimed
WO-2023192314-A1 LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS INIPHARM, INC. (US) 2023-10-05 WO claimed
WO-2025227044-A1 BIOACTIVE LIPIDS, SYSTEMS AND METHODS OF OBTAINING BIOACTIVE LIPIDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-10-30 WO disclosed
US-20250216407-A1 LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS INIPHARM, INC. 2025-07-03 US disclosed
EP-3335140-B1 SYSTEMS, APPARATUS, AND METHODS FOR ANALYZING AND PREDICTING CELLULAR PATHWAYS MASSACHUSETTS INST TECHNOLOGY (US) 2025-02-19 EP disclosed
US-20230375561-A1 METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES KADDURAH DAOUK RIMA F (US) 2023-11-23 US disclosed
WO-2023192314-A1 LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS INIPHARM, INC. (US) 2023-10-05 WO disclosed
WO-2016033605-A1 IMPROVED ASPHALT PRODUCTS AND MATERIALS AND METHODS OF PRODUCING THEM IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC. (US) 2016-03-03 WO disclosed
US-9149019-B2 Method of eliminating cat urine odor JMR, LC (US) 2015-10-06 US disclosed
US-20130323194-A1 METHOD OF ELIMINATING CAT URINE ODOR CO2 TECHNOLOGIES, INC. (US) 2013-12-05 US disclosed
US-20070066170-A1 CO2 GENERATING ABSORBENT PADS CO2 TECHNOLOGIES, INC. (US) 2007-03-22 US disclosed
US-7189666-B2 CO2 generating absorbent pads CO2 TECHNOLOGIES (US) 2007-03-13 US disclosed
US-7160939-B2 Preservatives; mixture of carbon dioxide in polymer matrix; mixture containing citric acid, calcium carbonate and low density polyethylene CO2 TECHNOLOGIES, INC. 2007-01-09 US disclosed
WO-2005005520-A2 ACTIVE MASTERBATCH FOR PRODUCTION OF CO2 GENERATING MASTERBATCH CO2 TECHNOLOGIES, INC. (US) 2005-01-20 WO disclosed
US-20050001204-A1 Active masterbatch for production of CO2 generating masterbatch CO2 TECHNOLOGIES, INC. (US) 2005-01-06 US disclosed
WO-2004110876-A2 CO2 GENERATING ABSORBENT PADS CO2 TECHNOLOGIES, INC. (US) 2004-12-23 WO disclosed
US-20040247750-A1 CO2 generating absorbent pads CO2 TECHNOLOGIES, INC. 2004-12-09 US disclosed
US-6797235-B2 Device and methods for modifying an atmosphere CO2 TECHNOLOGIES, INC. 2004-09-28 US disclosed
WO-2004022112-A1 DEVICE AND METHODS FOR MODIFYING AN ATMOSPHERE CO2 TECHNOLOGIES, INC. (US) 2004-03-18 WO disclosed
US-20040047760-A1 Device and methods for modifying an atmosphere LONGER SHELF LIFE, LLC 2004-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230375561-A1 METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES SLC25A20, CPT2, NDUFAB1 MAPT 1858/4885ALDH1A1 476/4885F7 4849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.